FOSUN HEALTH Logo

Atrial Fibrillation & Arrhythmia Diagnosis

catalogue

Atrial Fibrillation & Arrhythmia Diagnosis

Atrial Fibrillation & Arrhythmia Diagnosis

The diagnosis of atrial fibrillation is not one test but the answer to four separate questions: is this rhythm atrial fibrillation, how much of the time is it present, what kind of heart is carrying it, and what risk does it create. The tests are chosen to match the patient's episodes rather than the clinic's convenience — which is why someone whose episodes come once a month needs a different recording from someone whose pulse is irregular every morning. This page sets out each tool, what it answers and what it cannot do, and how the stroke-risk assessment is put together.

The pulse and the tracing: what each of them settles

The work begins with the pulse and the tracing, and both are needed. Feeling an irregularly irregular pulse raises the suspicion; it does not name the rhythm. Atrial fibrillation, atrial flutter with a variable response, and frequent ectopic beats can each produce an uneven pulse, and they are treated differently — so the electrocardiogram is what converts a suspicion into a diagnosis.

A 12-lead electrocardiogram recorded while the patient is actually in the rhythm is therefore the single most valuable test in the whole pathway. It shows the disorganised atrial activity and the irregular ventricular response that define the condition, and it also shows everything else the tracing happens to contain — a previous infarction, a conduction delay, an enlarged chamber — each of which can change the plan. An electrocardiogram taken on a symptom-free day is still worth having as a baseline, but it cannot do the work of a tracing captured during an episode.

Two limits belong here. A normal electrocardiogram in someone whose episodes are paroxysmal is common and expected, so it never closes the question. And in a patient whose pulse is fast enough to be uncomfortable, the tracing recorded in an emergency department answers a second and more urgent question at the same time: whether the rate is dangerous now, and whether the rhythm is coming from the atria or the ventricles.

Ambulatory monitoring: matching the recording to the pattern

When the rhythm comes and goes, the whole problem becomes one of coverage: the recording has to be long enough to overlap an episode. The choice of monitor therefore follows a single rule — match the duration to the frequency of the symptoms — and the commonest reason a diagnosis is delayed is that the recording was shorter than the pattern.

A monitor is also only useful if the patient can mark the moment. Almost all of them provide a button or an app to press when symptoms begin, and that one action is what allows a technician to find the right ten seconds among tens of thousands. Without it, a report may contain a brief run of an abnormal rhythm at three in the morning and leave unanswered the question of whether it caused anything at all.

Recording Usual duration Best suited to
24-hour Holter A single day Symptoms that occur most days; also used to measure the overall rate through the day and to look for long pauses
Patch monitor One to two weeks Symptoms that occur every few days; there are no leads to detach, so the recording is rarely interrupted
Event or handheld recorder Weeks, activated only during symptoms Rare episodes, where the patient can tell when one is starting and can record on demand
Implantable loop recorder Months to years Infrequent unexplained episodes, including black-outs, or the search for a rhythm after a stroke when nothing has been captured

Two practical points decide whether a monitoring period was worth its cost. The first is that the diary and the recording are always read together: an episode that lines up with the patient's own note is worth far more than one discovered by chance. The second is that a monitor which shows nothing is not a negative result. It is a statement about coverage, and it usually means the monitor was the wrong length for the pattern rather than that the heart is innocent.

Describing the heart that carries the rhythm

Once the rhythm has been named, the next question is what kind of heart is carrying it, because that is what decides between the available treatments. A transthoracic echocardiogram answers most of it: the size of the left atrium, the function of the ventricles, the state of the valves, and whether the right side of the heart is under strain. An atrium that is already enlarged, or a mitral valve that is already leaking, changes which options remain realistic and which ones are worth attempting.

Blood tests in atrial fibrillation are not routine box-ticking; several of them change treatment directly. Thyroid function is the clearest example, because an overactive thyroid can both provoke the rhythm and make it harder to control until the thyroid itself is treated. Kidney and liver function determine which anticoagulant is suitable and how it should be dosed. The blood count matters twice over: anaemia produces a fast pulse, and a low platelet count or a bleeding tendency changes the safety of any anticoagulant. Electrolytes explain some arrhythmias entirely, particularly in patients taking diuretics, and blood sugar and cholesterol belong to the same visit because they are the same risk conversation.

A transoesophageal echocardiogram belongs to a specific moment rather than to the routine. It looks at the left atrium and its appendage from inside the oesophagus, immediately behind the heart, which is the only view that reliably shows whether a clot is sitting in the appendage — and that question has to be answered before a cardioversion or an ablation, when restoring a normal rhythm could otherwise dislodge a clot into the circulation. The same test is used when a stroke is being investigated and the heart is one of the suspected sources.

How stroke risk is assessed, and why the score is not the decision

The stroke-risk assessment is deliberately kept apart from everything else, because it is the one part of the diagnostic work that does not depend on symptoms, on rhythm burden or on any imaging result. It is built from the patient's history, and it is repeated whenever that history changes.

The tool is a structured checklist known by its initials, CHA₂DS₂-VASc. Its letters stand for the factors that have been shown to travel with stroke risk in atrial fibrillation: C for heart failure, H for high blood pressure, A₂ for age, D for diabetes, S₂ for a previous stroke or transient ischaemic attack, V for vascular disease, the second A for age at a heavier weighting, and Sc for female sex. Each factor present is recorded and counted, and the total is used to structure the conversation about anticoagulation — not to issue the decision by itself.

Three things are worth understanding about how the score is used. First, it describes a risk carried by the patient rather than by today's tracing, which is why it is completed even when the rhythm is currently normal. Second, it is not a self-scoring exercise: several of the letters ask for findings a patient cannot assess alone, and the weightings are not simple counts. Third, it is never read on its own. Against it sits a parallel assessment of bleeding risk — age, kidney function, previous bleeding, and medicines that add to the risk — because what the clinician is doing is balancing two risks rather than eliminating one.

What the assessment produces is therefore not a verdict but a documented discussion: which factors apply, what each contributes, what the patient's own priorities are, and what has been agreed. Where the balance is genuinely close, that is written down too, and it is revisited at each review rather than settled once. The arrangements that follow an agreed plan are set out on the treatment options page and in the prevention and follow-up page.

When an electrophysiology study is needed

An electrophysiology study is not part of the diagnosis for most patients with atrial fibrillation; the surface tracings are usually enough. It becomes relevant in three situations: when a surface recording is genuinely ambiguous, when a regular narrow-complex tachycardia must be identified precisely before it is treated, and when an ablation is being planned and the anatomy of the pulmonary veins and any additional circuits have to be mapped.

In the study, fine catheters are passed into the heart through the veins at the groin and positioned against the inner surface, where they record electrical activity directly and can pace the heart in a controlled way. What comes out is a map: where the impulses originate, which pathways carry them, and where a short circuit sits. In supraventricular tachycardia this can identify something that a small targeted procedure can remove; in atrial fibrillation it confirms the pulmonary veins as the target and finds additional circuits — an atrial flutter, for example — that would otherwise be left untreated.

The distinction to hold on to is that a study is an investigation with a therapeutic purpose in view, not an automatic next step after a diagnosis. It carries the small risks of any catheter procedure, and it is worth performing when the answer will change what is done — a question to settle with the team beforehand rather than afterwards.

What a completed assessment should be able to state

A completed assessment should be able to state five things plainly. If the report answers only the first of them, the treatment decision has not in fact been made.

  • What the rhythm is — named from a tracing rather than from a description, and with a note of whether a flutter circuit is present alongside it.
  • How much of the time it is present — the burden, from monitoring, with the patient's own diary attached and the episodes dated.
  • What kind of heart is carrying it — atrial size, valve function and ventricular function from the echocardiogram, together with the blood tests that could explain or confound the rhythm.
  • What the stroke risk is — the risk factors recorded in the structured checklist, the bleeding-risk assessment beside them, and the plan that was agreed written down.
  • What is reversible — thyroid, blood pressure, sleep apnoea, alcohol and contributing medicines, each either addressed or explicitly excluded.

The reason for insisting on all five is that each of them can overturn a plan built on the others. A rhythm that is really flutter changes the target of an ablation. A large, fibrous atrium changes how much weight to put on a drug compared with a procedure. A thyroid that was never checked can keep the rhythm going whatever else is done. And a risk assessment that was never performed leaves the most consequential decision of all — the one about stroke — unmade, however thorough everything else has been.

Frequently Asked Questions

What if every test comes back normal and I still have symptoms?

That is common, and it usually means the recording was shorter than the pattern rather than that there is nothing to find. A rhythm that appears once a month will almost never be captured on a 24-hour monitor. The practical answer is longer coverage — a patch monitor worn for a fortnight, a handheld device used when symptoms start, or an implantable recorder where the episodes are rare and the question matters. It is also worth keeping a diary, because the episodes that line up with symptoms are the ones that count.

Do I need a catheter study to be diagnosed?

Usually not. Atrial fibrillation is diagnosed from surface recordings — an electrocardiogram during symptoms or ambulatory monitoring — and an electrophysiology study is reserved for cases where the surface picture is genuinely ambiguous, or where it is being done as part of planning a procedure. It is an invasive test performed through catheters placed inside the heart, so it has a purpose rather than a routine place. If it is proposed, it is reasonable to ask what specific question it is meant to answer and what would change as a result.

How is my stroke risk worked out, and why does it matter so much?

It is worked out from your history rather than from your symptoms, using a structured checklist that records the factors known to travel with stroke risk in atrial fibrillation — among them heart failure, blood pressure, age, diabetes, a previous stroke or TIA, vascular disease and sex. A parallel assessment of bleeding risk is made at the same time, because the choice about anticoagulation is a balance between two risks. It matters so much because this is the one decision in atrial fibrillation that protects against the outcome patients fear most, and because it applies even when the rhythm has never caused a single symptom.

Can a smartwatch or an ECG app diagnose this?

A wearable can detect an irregular rhythm and can be genuinely useful evidence — a recording of an episode is exactly what the assessment has been missing, and the date and time stored with it make it more valuable still. What it cannot do is replace the confirmation: a diagnosis is made from a clinical-grade recording, and a single-lead device can miss rhythms, or flag changes that are not atrial fibrillation. The sensible response to a device flagging an irregular pulse is to keep the recording, note when it happened, and take it to an assessment rather than to treat it as a diagnosis or to dismiss it.

Patient Stories

Stories from our atrial fibrillation arrhythmia programme, pulled automatically from the patient story library by disease tag.

View all patient stories →

Send every tracing, with the dates attached

Send the electrocardiograms, the monitor reports and the watch recordings with their dates and times, the echocardiogram, the thyroid and kidney results, and the medication list. A cardiology team will return a written opinion: what the rhythm is, whether the coverage was long enough to be sure, what the stroke-risk factors are, and which tests still need to be done.

Want to see the whole process first? Your full medical journey, step by step →

Book an Appointment Request a Video Consultation

Follow Fosun Health

Apply for an Appointment

Do you have test results*